Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation,
which affects approximately 1% of the population. The benefit of early recognition and …

Current guidelines for the management of rheumatoid arthritis (RA) recommend early
treatment and a treat-to-target goal of remission or low disease activity. Over the past …

Background Rheumatoid arthritis is the most common autoimmune disease worldwide and
requires long-term treatment to suppress inflammation. Currently, treatment is started when …

Abstract Purpose of Review The purpose of this study was to review the current information
on fatigue in rheumatoid arthritis (RA). Recent Findings Severe fatigue is common among …

Fatigue in rheumatoid arthritis appears to be largely because of factors outside the direct
effects of the disease, such as behavioral and psychological factors. In spite of the …

Background Based on different genetic and environmental risk factors and histology, it has
been proposed that rheumatoid arthritis (RA) consists of 2 types: autoantibody-positive and …

Fatigue is one of the most important symptoms for patients with RA, and imposes a great
burden on patients' lives, being associated with significantly reduced health-related quality …

Objective. To summarize patients' preferences for disease-modifying antirheumatic drug
(DMARD) therapy in rheumatoid arthritis (RA). Methods. We conducted a systematic review …

Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor recently approved by
the European Medicine Agency and the Food and Drug Administration for the treatment of …

Patients with rheumatoid arthritis (RA) may experience residual pain and functional
impairment despite good control of disease activity. This study compared improvements in …